Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 3;20(13):6287.
doi: 10.3390/ijerph20136287.

Syndromic Surveillance of Health Effects Due to Summer Sun Overexposure: Construction of an Indicator Based on Drug Sales in Pharmacies-Preliminary Study within the PRISME Project

Adeline Riondel  1 , Leslie Simac  1 , Olivier Catelinois  1 , Carole Morlan-Salesse  2 , Frédéric Bounoure  3 , Bruno Galan  4 , Damien Mouly  1
Affiliations

Syndromic Surveillance of Health Effects Due to Summer Sun Overexposure: Construction of an Indicator Based on Drug Sales in Pharmacies-Preliminary Study within the PRISME Project

Adeline Riondel et al. Int J Environ Res Public Health. .

Abstract

Introduction: Solar radiation is classified as a known human carcinogen. In France, people frequently ask local pharmacies to dispense products for sunburns. In the PRISME project, studying this use can be a specific and sensitive way to assess these overexposures.

Objective: This study aims to construct an indicator for monitoring healthcare consumption in pharmacies after overexposure to solar UV.

Methods: The study, conducted between July and August 2019, covered a sample of pharmacies located in coastal communities of southern France. A list of products for sunburn was defined. When one of the products on this list was sold, the customer was asked to fill out a questionnaire to determine whether the purchase was related to UV overexposure. A positive predictive value (PPV) per active ingredient was calculated.

Results: Overall, nine pharmacies participated in the study, and 288 questionnaires were collected. The majority of products purchased were for women (60.7%), for people aged 15 and over (78.1%), and for people not living in the department (68.9%). The most frequently purchased products were our trolamine-containing products which accounted for 53% of sales. With the exception of three products, all PPVs were greater than 0.8.

Conclusion: The high PPV confirms the suitability of the product selection as an indicator for monitoring healthcare consumption related to solar UV overexposure. Two indicators (one sensitive and one specific) were selected to maximise the chances of identifying UV-related remedies.

Keywords: health care consumption; health care use; health impact; medicines; pharmacy; solar UV; sunburn.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Questionnaire filled out by the pharmacist interviewing the person who was buying the product.
See this image and copyright information in PMC

References

    1. Beck F., Gautier A. Baromètre Cancer 2010. Inpes; Saint Denis, France: 2012. 272p
    1. Binder Foucard F., Belot A., Delafosse P., Remontet L., Woronoff A.S., Bossard N. Estimation Nationale de L’incidence et de la Mortalité par Cancer en France Entre 1980 et 2012. Etude à Partir des Registres des Cancers du Réseau Francim—Partie 1: Tumeurs Solides. Institut de Veille Sanitaire; Saint-Maurice, France: 2013.
    1. Jéhannin-Ligier K., Dantony E., Bossard N., Molinié F., Defossez G., Daubisse-Marliac L., Delafosse P., Remontet L., Uhry Z. Projection de L’incidence et de la Mortalité par Cancer en France Métropolitaine en 2017. Santé Publique France; Saint-Maurice, France: 2017.
    1. Autier P., Boffetta P., Boniol M., Boyle P., Ferlay J., Aurengo A. Attributable Causes of Cancer in France in the Year 2000. IARC Press; Lyon, France: 2007. 172p
    1. Cancer IAfRo. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans . IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC; Lyon, France: 2012. No. 100D.:363.